Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of peroral Vorinostat (Zolinza) in refractory histone deacetylase-positive uterine sarcoma
2016-000782-22Phase 2Terminated
- Sponsor
- Medical University of Graz
- Start
- Dec 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in uterine sarcoma, sponsored by Medical University of Graz. Primary endpoints: Progression-free survival at 3 months, Progression-free survival at 6 months and 1 more. Started Dec 2016; status: terminated.
02
Drugs
vorinostat
03
Conditions
uterine sarcoma
Beyond the preview
Go deeper on 2016-000782-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000782-22.